Trial Profile

Phase III trial of arterolane/piperaquine versus artemether/lumefantrine in patients aged ≥12 years with acute uncomplicated Plasmodium falciparum malaria

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Jan 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Arterolane/piperaquine (Primary) ; Artemether/lumefantrine
Indications Falciparum malaria
Focus Registrational; Therapeutic Use
Sponsors Ranbaxy Laboratories

Most Recent Events

20 Jan 2015 New trial record
15 Dec 2014 Results published in Ranbaxy Laboratories media release.
15 Dec 2014 Based on data from this trial, arterolane/piperaquine [Synriam] has been launched in seven African countries (Nigeria, Uganda, Senegal, Cameroon Guinea, Kenya and Ivory Coast), according to a Ranbaxy Laboratories media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com